Stent thrombosis relation to antiplatelet medications

Revision as of 15:27, 1 June 2011 by Lakshmi Gopalakrishnan (talk | contribs) (New page: {{SI}} {{CMG}} '''Associate Editors-In-Chief:''' Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S. {{Editor Help}} ==Incidence of stent thrombosis while on dual antipla...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Stent thrombosis relation to antiplatelet medications

Articles

Most recent articles on Stent thrombosis relation to antiplatelet medications

Most cited articles on Stent thrombosis relation to antiplatelet medications

Review articles on Stent thrombosis relation to antiplatelet medications

Articles on Stent thrombosis relation to antiplatelet medications in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Stent thrombosis relation to antiplatelet medications

Images of Stent thrombosis relation to antiplatelet medications

Photos of Stent thrombosis relation to antiplatelet medications

Podcasts & MP3s on Stent thrombosis relation to antiplatelet medications

Videos on Stent thrombosis relation to antiplatelet medications

Evidence Based Medicine

Cochrane Collaboration on Stent thrombosis relation to antiplatelet medications

Bandolier on Stent thrombosis relation to antiplatelet medications

TRIP on Stent thrombosis relation to antiplatelet medications

Clinical Trials

Ongoing Trials on Stent thrombosis relation to antiplatelet medications at Clinical Trials.gov

Trial results on Stent thrombosis relation to antiplatelet medications

Clinical Trials on Stent thrombosis relation to antiplatelet medications at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Stent thrombosis relation to antiplatelet medications

NICE Guidance on Stent thrombosis relation to antiplatelet medications

NHS PRODIGY Guidance

FDA on Stent thrombosis relation to antiplatelet medications

CDC on Stent thrombosis relation to antiplatelet medications

Books

Books on Stent thrombosis relation to antiplatelet medications

News

Stent thrombosis relation to antiplatelet medications in the news

Be alerted to news on Stent thrombosis relation to antiplatelet medications

News trends on Stent thrombosis relation to antiplatelet medications

Commentary

Blogs on Stent thrombosis relation to antiplatelet medications

Definitions

Definitions of Stent thrombosis relation to antiplatelet medications

Patient Resources / Community

Patient resources on Stent thrombosis relation to antiplatelet medications

Discussion groups on Stent thrombosis relation to antiplatelet medications

Patient Handouts on Stent thrombosis relation to antiplatelet medications

Directions to Hospitals Treating Stent thrombosis relation to antiplatelet medications

Risk calculators and risk factors for Stent thrombosis relation to antiplatelet medications

Healthcare Provider Resources

Symptoms of Stent thrombosis relation to antiplatelet medications

Causes & Risk Factors for Stent thrombosis relation to antiplatelet medications

Diagnostic studies for Stent thrombosis relation to antiplatelet medications

Treatment of Stent thrombosis relation to antiplatelet medications

Continuing Medical Education (CME)

CME Programs on Stent thrombosis relation to antiplatelet medications

International

Stent thrombosis relation to antiplatelet medications en Espanol

Stent thrombosis relation to antiplatelet medications en Francais

Business

Stent thrombosis relation to antiplatelet medications in the Marketplace

Patents on Stent thrombosis relation to antiplatelet medications

Experimental / Informatics

List of terms related to Stent thrombosis relation to antiplatelet medications

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editors-In-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.


Incidence of stent thrombosis while on dual antiplatelet therapy

Clinical trial data: Incidence of EARLY ST

This category would include the incidence of acute and subacute stent thrombosis.

  • In a prospective observational cohort study of 2229 patients with DES (sirolimus or paclitaxel)[1], ST occurred in 1.3% with a 0.6% subacute ST in patients who were on dual antiplatelet therapy.
  • In a long-term follow-up study of 1911 patients with DES on dual antiplatelet therapy[2], stent thrombosis occurred in 0.8% patients after DES implantation with 1.3% stent thrombosis within 6 hours to 20.4 months. The incidence of ST was 3.3% in patients with complete discontinuation of antiplatelet therapy, 7.8% in patients with premature discontinuation and 0.6% in patients who did not discontinue antiplatelet therapy
  • Results from an observational study involving 15157 patients with sirolimus-eluting stents (SES) [3], reported that the rates of acute ST was 0.13% and subacute ST was 0.56%, representing a 12-month actuarial incidence of 0.87%. Thereby suggests a high degree of safety of SES, with a rate of stent thrombosis similar to that observed in randomized trials.


Clinical trial data: Incidence of LATE ST

This category would include the incidence of late and very late stent thrombosis.

  • In a cohort[4] of 2006 patients with PES and SES up to a mean follow-up of 15 months with a follow up rate of 98% of the patients, no ST occurred while patients were on dual antiplatelet therapy.
  • In a long-term follow-up study of 1911 patients with DES on dual antiplatelet therapy[2], ST occurred in 0.8% patients after DES with the 0.6% of late stent thrombosis, which was similar to that for BMS.


Incidence of stent thrombosis while on single antiplatelet therapy

Clinical trial data: Incidence of EARLY ST

This category would include acute and subacute ST while on single antiplatelet therapy.

  • This is an uncommon category as most patients are on dual antiplatelet medications.How ever it has been suggested that those patients who:
    • suboptimally loaded with dual antiplatelet therapy,
    • receive bivalirudin, may be at an increased risk of ST during the waning of the effect of bivalirudin and
    • during the time period until dual antiplatelet effects becomes adequate.
    • Another scenario is the patient who is intolerant to one antiplatelet medication. This again is a very uncommon situation, as hospitals use aspirin desensitization.


Clinical trial data: Incidence of LATE ST

This category would include late ST and very late ST.

  • Overall the incidence of late ST in patients who presented on aspirin monotherapy was 0.25%. How ever no data was reported as to the proportion of patients who were on aspirin monotherpay at that time. 60% of the patients who presented with late ST and were on aspirin monotherpay after 6 months of the procedure. It is possible that the majority of the patients may have been on aspirin monotherapy at that time, yielding an incidence of ST for this group of 0.25%[1].
  • In a study involving 1911 patients who had DES 0.15% of patients who presented with late ST were on one antiplatelet therapy. How ever it is not clear as to the number of patients in the whole cohort who were on single antiplatelet therapy[1]. In one study, hazard ratio for late ST on premature discontinuation of antiplatelet therapy was 57.13 (14.84 - 219.96) [1].


Incidence of stent thrombosis with no antiplatelet therapy

Clinical trial data: Incidence of EARLY ST

  • This is an unlikely scenario in the current environment.


Clinical trial data: Incidence of LATE ST

  • On long term follow up to 19.4 months, 121 patients with DES had complete interruption of antiplatelet therapy with a ST rate of 3.3 % in that group. (this represented an overall risk of 0.2 % when applied to the whole study population.) In the same group the rate of ST when both antiplatelet therapies were stopped within 6 months of stent implantation was 9%[2].
  • Two patients presented with ST who were 343 and 335 days following DES implantation. They had ceased dual antiplatelet therapy within 14 days of ST . Data of other patients who had a DES with no antiplatelet cover for the same duration was not available[5].


References

  1. 1.0 1.1 1.2 1.3 Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G; et al. (2005). "Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents". JAMA. 293 (17): 2126–30. doi:10.1001/jama.293.17.2126. PMID 15870416.
  2. 2.0 2.1 2.2 Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW; et al. (2006). "Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up". Am J Cardiol. 98 (3): 352–6. doi:10.1016/j.amjcard.2006.02.039. PMID 16860022.
  3. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J; et al. (2006). "Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry". Circulation. 113 (11): 1434–41. doi:10.1161/CIRCULATIONAHA.104.532242. PMID 16534015.
  4. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW (2005). "Late angiographic stent thrombosis (LAST) events with drug-eluting stents". J Am Coll Cardiol. 45 (12): 2088–92. doi:10.1016/j.jacc.2005.02.086. PMID 15963413.
  5. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T; et al. (2004). "Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy". Lancet. 364 (9444): 1519–21. doi:10.1016/S0140-6736(04)17275-9. PMID 15500897.

Template:WH Template:WS